GLP-1 drugs shown to aid sleep apnea, liver and kidney health
Researchers at Pennington Biomedical Research Center reported that GLP-1 drugs may improve sleep apnea, liver health and kidney outcomes, while other claimed benefits remain unproven. Earlier analyses of national health data suggested a modest decline in adult obesity rates in 2023 that coincided with increased use of GLP-1 medications, though experts warned the trend’s durability was uncertain.
A Wells Fargo analysis found GLP-1 use for obesity more than doubled since 2022, making obesity treatments the largest late-stage drug pipeline segment and reducing bariatric surgery volumes. Additional research showed GLP-1 drugs cutting bariatric surgery numbers, improving cardiovascular outcomes and prompting shifts in payer coverage, and also noted effects such as reduced alcohol intake and arthritis relief alongside concerns about nutrient deficiencies and muscle loss.
